Wuhan Healthgen Biotechnology Corp. (SHA:688765)
China
· Delayed Price · Currency is CNY 78.58
+0.62 (0.80%)
At close: Dec 5, 2025
SHA:688765 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 132.37 | 160.4 | 235.97 | 387.56 | 243.41 | 150.71 | Upgrade
|
| Cash & Short-Term Investments | 132.37 | 160.4 | 235.97 | 387.56 | 243.41 | 150.71 | Upgrade
|
| Cash Growth | -43.91% | -32.02% | -39.11% | 59.22% | 61.51% | 950.02% | Upgrade
|
| Accounts Receivable | 6.36 | 0.14 | 0.2 | 0.09 | 0.02 | 0.02 | Upgrade
|
| Other Receivables | 0.98 | 0.35 | 0.35 | 0.29 | 0.77 | 0.17 | Upgrade
|
| Receivables | 7.34 | 0.49 | 0.55 | 0.38 | 0.79 | 0.19 | Upgrade
|
| Inventory | 80.63 | 50.02 | 35.73 | 25.66 | 12.52 | 13.37 | Upgrade
|
| Other Current Assets | 41.24 | 26.43 | 16.42 | 34.78 | 26.49 | 5.81 | Upgrade
|
| Total Current Assets | 261.58 | 237.34 | 288.67 | 448.38 | 283.21 | 170.07 | Upgrade
|
| Property, Plant & Equipment | 841.2 | 733.42 | 606.23 | 580.78 | 208.24 | 43.24 | Upgrade
|
| Other Intangible Assets | 85.72 | 87.39 | 66.24 | 68.08 | 24.53 | 26.23 | Upgrade
|
| Long-Term Deferred Charges | 3.2 | 3.56 | 0.07 | - | - | - | Upgrade
|
| Other Long-Term Assets | 125.56 | 0.1 | 0.99 | 5.43 | 77.16 | 0.17 | Upgrade
|
| Total Assets | 1,317 | 1,062 | 962.2 | 1,103 | 593.13 | 239.71 | Upgrade
|
| Accounts Payable | 199.27 | 175.9 | 105.77 | 169.84 | 122.1 | 5.58 | Upgrade
|
| Accrued Expenses | 4.98 | 9.06 | 9.56 | 7.88 | 6.05 | 5.7 | Upgrade
|
| Short-Term Debt | 15.01 | 10.01 | - | - | - | 0.1 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | 1.07 | 1.02 | - | 0.31 | Upgrade
|
| Current Portion of Leases | - | - | 0.29 | 0.55 | 0.37 | - | Upgrade
|
| Current Unearned Revenue | 2.4 | 2.45 | 1.92 | 2.44 | 1.1 | 5.14 | Upgrade
|
| Other Current Liabilities | 51.14 | 35.24 | 2.09 | 9.09 | 2.02 | 1.12 | Upgrade
|
| Total Current Liabilities | 272.79 | 232.67 | 120.7 | 190.82 | 131.63 | 17.95 | Upgrade
|
| Long-Term Debt | 470.79 | 184 | 90.12 | 13.13 | - | 9.6 | Upgrade
|
| Long-Term Leases | 19.47 | 19.29 | 2.45 | 0.54 | 0.39 | - | Upgrade
|
| Long-Term Unearned Revenue | 21.81 | 23.02 | 15.83 | 1.43 | 1.79 | 3.93 | Upgrade
|
| Other Long-Term Liabilities | 1.49 | 1.49 | 1.49 | 1.49 | - | - | Upgrade
|
| Total Liabilities | 786.35 | 460.46 | 230.58 | 207.41 | 133.81 | 31.48 | Upgrade
|
| Common Stock | 268.05 | 268.05 | 268.05 | 268.05 | 239.13 | 55.89 | Upgrade
|
| Additional Paid-In Capital | 1,196 | 1,185 | 1,164 | 1,140 | 589.64 | 387.76 | Upgrade
|
| Retained Earnings | -932.99 | -851.36 | -699.99 | -513.03 | -369.45 | -235.42 | Upgrade
|
| Shareholders' Equity | 530.91 | 601.35 | 731.62 | 895.26 | 459.32 | 208.23 | Upgrade
|
| Total Liabilities & Equity | 1,317 | 1,062 | 962.2 | 1,103 | 593.13 | 239.71 | Upgrade
|
| Total Debt | 505.27 | 213.3 | 93.93 | 15.25 | 0.76 | 10.01 | Upgrade
|
| Net Cash (Debt) | -372.9 | -52.89 | 142.04 | 372.31 | 242.65 | 140.69 | Upgrade
|
| Net Cash Growth | - | - | -61.85% | 53.44% | 72.47% | 5104.02% | Upgrade
|
| Net Cash Per Share | -1.38 | -0.20 | 0.53 | 1.43 | 1.12 | 2.82 | Upgrade
|
| Filing Date Shares Outstanding | 272.09 | 269.59 | 268.05 | 261.05 | 268.05 | 49.86 | Upgrade
|
| Total Common Shares Outstanding | 272.09 | 269.59 | 268.05 | 261.05 | 239.13 | 49.86 | Upgrade
|
| Working Capital | -11.22 | 4.68 | 167.97 | 257.57 | 151.58 | 152.12 | Upgrade
|
| Book Value Per Share | 1.95 | 2.23 | 2.73 | 3.43 | 1.92 | 4.18 | Upgrade
|
| Tangible Book Value | 445.19 | 513.96 | 665.38 | 827.18 | 434.8 | 182.01 | Upgrade
|
| Tangible Book Value Per Share | 1.64 | 1.91 | 2.48 | 3.17 | 1.82 | 3.65 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.